NCT06224634 The Effect of Anti-IL17 on Airway Hyperresponsiveness and Resistance
| NCT ID | NCT06224634 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Copenhagen University Hospital, Hvidovre |
| Condition | Asthma |
| Study Type | OBSERVATIONAL |
| Enrollment | 74 participants |
| Start Date | 2024-08-02 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 74 participants in total. It began in 2024-08-02 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This observational longitudinal cohort study aims to assess the effect of monoclonal antibodies targeting interleukin 17 (anti-IL-17) on airway hyperreactivity and airway resistance. The study involves adult participants suffering from dermatological or rheumatological illness, who are planning to start treatment with monoclonal antibodies targeting interleukin 17 as a part of the treatment of these diseases. The primary outcome of this study will be changes in airway hyperresponsiveness to methacholine challenge reported as response-dose-ratio before and after initiation of anti-IL17 treatment regardless of presence of respiratory disease. Furthermore, the potential effect of anti-IL-17 on airway resistance will be assessed using conventional spirometry for measuring changes in FEV1 and Airwave oscillometry. A reduced degree of airway hyperreactivity and airway resistance after initiating ani-IL-17 could indicate effectiveness of anti-IL-17 in asthma patients which would have to be examined further in a population of asthma patients.
Eligibility Criteria
Inclusion Criteria: * Patients planning to start treatment with anti-IL-17 antibodies Exclusion Criteria: * Current pregnancy * FEV1 \< 1.5L or less than 60% of predicted value expected. * Previous anaphylactic shock or severe allergic reaction to medicine * Uncontrolled hypertension * Myocardial infarction or stroke within the last 3 months * Known aortic aneurysm * Recent eye surgery or risk of elevated intracranial pressure * Treatment with systemic corticosteroids within 6 weeks
Contact & Investigator
Jonas A Baekdal, MD
PRINCIPAL INVESTIGATOR
University hospital, Hvidovre
Frequently Asked Questions
Who can join the NCT06224634 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Asthma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06224634 currently recruiting?
Yes, NCT06224634 is actively recruiting participants. Contact the research team at jonas.aggerholm.baekdal.02@regionh.dk for enrollment information.
Where is the NCT06224634 trial being conducted?
This trial is being conducted at Hvidovre, Denmark.
Who is sponsoring the NCT06224634 clinical trial?
NCT06224634 is sponsored by Copenhagen University Hospital, Hvidovre. The principal investigator is Jonas A Baekdal, MD at University hospital, Hvidovre. The trial plans to enroll 74 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.